TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04158102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome injectable suspension
Description: Single dose of Bupivacaine liposome injectable suspension 266 mg in 20 mL
Study: NCT01511874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELIGARD 22.5mg
Description: a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
Study: NCT00150800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 10 mg and 25 mg~* Route of Administration: Oral
Study: NCT03410095

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI, cognitive testing, bloodwork
Description: Participants will undergo 3-Tesla MRI. Scan time will be about 1 hour and 15 minutes per subject per session at the Sunnybrook site. The protocol is designed to image SVD burden by quantifying PVS and WMH volumes, and image various physiological estimates on the brain.~Participants will undergo the following cognitive tests: Behavioural Neurology Assessment-R (BNA-R), Montreal Cognitive Assessment (MOCA), Center for Epidemiologic Studies Depression Scale (CES-D), and BrainScreen.~Blood samples will be assayed for inflammatory and endothelial function. Classical vascular risk factors will also be assessed. Once data collection is complete, DNA will be extracted from the frozen PBMC fraction and will be genotyped for APOE genotype and a panel of other single nucleotide polymorphisms known to be associated with cognition and cerebrovascular disease.
Study: NCT03263481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraductal secretin test (IDST)
Description: If pancreatic duct entry incidentally occurs during the clinically scheduled ERCP and the pancreatic duct appears normal, an IDST will be performed for study purposes. An IDST consists of the administration of human secretin, after which pancreatic juice is collected intraductally. In this study, the fluid will be collected through continuous aspiration in 5 minute intervals for 30 minutes. Samples will be collected at 5, 10, 15, 20, 25, and 30 minutes after secretin administration (6 collections in total).
Study: NCT03281499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: da Vinci Surgical System Model IS4000
Description: tailored radiotherapy regimen following transoral robotic surgery
Study: NCT02802579

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard protocol
Description: tube voltage: 120 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: enhanced protocol
Description: tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: enhanced obesity protocol
Description: tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 180° (with two detectors in a 90° angle)
Study: NCT01933529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA 290
Description: ARA 290 is injected s.c. once daily during the study period
Study: NCT01573065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling intervention with rapid HIV testing
Description: Counseling intervention (modeled after Brief Negotiation Interview and Project RESPECT-2) coupled with rapid HIV testing. Telephone booster at 2 weeks.
Study: NCT01933529

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARA 290
Description: ARA 290 is injected s.c. once daily during the study period
Study: NCT02773121

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Trainer-guided at-home behavioral intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Trainer-guided at-home behavioral intervention
Study: NCT02689752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib
Description: fruquintinib suspension, 5mg ( 100mCi), oral, taken once, fast
Study: NCT04708795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP701
Description: Preparation of Cannabis flowers (Cannabis flos)
Study: NCT01090765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Study: NCT02000830

Intervention type: DRUG
Intervention: Placebo
Description: Matching placebo administered by IM injection
Study: NCT04728178

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Crystalloid solution
Description: Crystalloid solution is a true solution and is able to pass through a semipermeable membrane.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid solution
Description: Crystalloid solution is a true solution and is able to pass through a semipermeable membrane.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colloid solution
Description: Colloid solution is a heterogeneous mixture whose particle size is intermediate between those of a solution and a suspension.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colloid solution
Description: Colloid solution is a heterogeneous mixture whose particle size is intermediate between those of a solution and a suspension.
Study: NCT03417947

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D bolus
Description: One single oral liquid vitamin D3 supplement of 300 000 IU

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical in taste and appearance to the vitamin D bolus
Study: NCT01090765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Study: NCT02401542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vofatamab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vofatamab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Study: NCT03875482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab 150 mg (150 mg/mL) in prefilled syringes, self-administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution for risankizumab
Description: Placebo solution in prefilled syringes, self-administered subcutaneously
Study: NCT01264380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: Single oral dose, fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: Single oral dose, with high fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: Continuous administration, orally twice daily
Study: NCT03875625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Use of the normal bariatric surgery procedures commonly conducted in our hospital, such as: Laparoscopic Roux-en-Y gastric bypass (RYGB) and Laparoscopic sleeve gastrectomy (LSG)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietitian led life style modification intervention
Description: Intensive 6 months life style changes supervised by diatitians.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietitian led life style modification intervention
Description: Intensive 6 months life style changes supervised by diatitians.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional care (control)
Description: receive routine care
Study: NCT04382924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP-120 (Ifenprodil)
Description: Ifenprodil, 20 mg TID Ifenprodil, 40 mg TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP-120 (Ifenprodil)
Description: Ifenprodil, 20 mg TID Ifenprodil, 40 mg TID
Study: NCT04469647

Intervention type: DIAGNOSTIC_TEST
Intervention: Serology Test
Description: Participants will be seen at T0 (baseline),T2 (2 months after T0), and T4 (2 months after T2).~at every visit, participants will be asked to complete a general surveillance survey and a blood sample will be taken for the serology test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serology Test
Description: Participants will be seen at T0 (baseline),T2 (2 months after T0), and T4 (2 months after T2).~at every visit, participants will be asked to complete a general surveillance survey and a blood sample will be taken for the serology test.
Study: NCT03434392

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Sensory Test 1
Description: Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Sensory Test 1
Description: Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.
Study: NCT02401542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02520271

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Activation
Description: BA consists of at least 4 intervention sessions with a focused, active working style by the therapist. The therapy initiation includes a focused interview targeting at determining 1-2 main problems, on which the therapy will be focused. Specific therapeutic methods for BA include the use ABC analysis, targeting at hitting the negative consequences of current problematic behavior and motivating for change. Further, recognizing the obstacles for change (TRAP) is the next method to be used. The therapist encourages the client for active behavioral monitoring through assigned homework during the therapy process. The final step and method used is strengthening the gained change (ACTION).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Activation
Description: BA consists of at least 4 intervention sessions with a focused, active working style by the therapist. The therapy initiation includes a focused interview targeting at determining 1-2 main problems, on which the therapy will be focused. Specific therapeutic methods for BA include the use ABC analysis, targeting at hitting the negative consequences of current problematic behavior and motivating for change. Further, recognizing the obstacles for change (TRAP) is the next method to be used. The therapist encourages the client for active behavioral monitoring through assigned homework during the therapy process. The final step and method used is strengthening the gained change (ACTION).
Study: NCT03434392

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Sensory Test 1
Description: Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Sensory Test 1
Description: Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Sensory Test 2
Description: Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.
Study: NCT02520271

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interview
Description: Motivational interview (MI) is a therapeutic intervention that focuses on resolving client ambivalence towards changing problematic behavior. MI involves a client-centered approach that encourages the client to develop his or her own motivation. The therapeutic alliance in MI is predominantly a partnership, rather than an expert/client dynamic.~MI has been studied primarily in addiction problems, but there are numerous reports of its efficacy in several chronic somatic conditions, and lifestyle problems.
Study: NCT01787825

Intervention type: DEVICE
Group type: OTHER
Intervention: PillCam SB2 capsule
Description: Capsule Endoscopy system

Intervention type: DEVICE
Group type: OTHER
Intervention: PillCam SB2 capsule
Description: Capsule Endoscopy system

Intervention type: DEVICE
Group type: OTHER
Intervention: CapsoCam SV-1
Description: Capsule endoscopy

Intervention type: DEVICE
Group type: OTHER
Intervention: CapsoCam SV-1
Description: Capsule endoscopy
Study: NCT03434392

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Sensory Test 2
Description: Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Sensory Test 2
Description: Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Sensory Test 2
Description: Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Sensory Test 3
Description: Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Sensory Test 3
Description: Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
Study: NCT01242202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha glucosidase inhibitor
Description: oral
Study: NCT04512534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody+ HDAC inhibitor
Description: Patients receive anti-PD-1 antibody Sintilimab+ HDAC inhibitor Chidamide three weeks for a cycle, detailed as follows:~* Anti-PD-1 antibody (Sintilimab): Fixed dose of 200 mg every 3 weeks, intravenous drip (without pretreatment), infusion time: 30 minutes (no less than 20 mins, no more than 60 mins), the maximum treatment period is 2 years (up to 35 doses), complete remission（CR）patients confirmed by imaging assessment can be considered off anti-PD-1 treatment after 12 treatment cycles.~* Chidamide: Chidamide is administered orally at a dose of 30mg (initial dose). It is recommended to be administered within 0.5h after a meal with a fixed time. Chidamide will be given until disease progression or intolerant toxicity. The maximum treatment is 2 years. If chidamide therapy requires to be continued over 2 years due to clinical benefit, the prescription/decision should be made after discussion with the principal investigator.
Study: NCT00680901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 5 pills at 250mg each once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 pills once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1700mg/m2/day in two daily doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: 1700mg/m2/day in two daily doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2 on day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: 130mg/m2 on day 1
Study: NCT04058652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical nerve stimulation (TENS) unit
Description: The transcutaneous electrical nerve stimulation (TENS) unit is a noninvasive, inexpensive, battery-operated device that was originally designed to provide modulation of the afferent nervous system to relieve pain. By providing alternating current through cutaneous electrodes, TENS activates large-diameter afferent fibers of the nervous system (A-delta, A-beta, C fibers), whose ascending signals are subsequently relayed to the central nervous system.
Study: NCT01864109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy*
Description: If local control includes RT, RT should be given concurrently with chemotherapy cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy*
Description: If local control includes RT, RT should be given concurrently with chemotherapy cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study: NCT04700995

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NiTi instruments
Description: Root canal filling removal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NiTi instruments
Description: Root canal filling removal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NiTi instruments
Description: Root canal filling removal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NiTi instruments
Description: Root canal filling removal
Study: NCT03434392

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Sensory Test 3
Description: Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
Study: NCT04306900

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTX-030, budigalimab and mFOLFOX6
Description: Dose and schedule per protocol

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTX-030, budigalimab and docetaxel
Description: Dose and schedule per protocol

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTX-030 and mFOLFOX6
Description: Dose and schedule per protocol

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTX-030 and budigalimab
Description: Dose and schedule per protocol

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTX-030, budigalimab, nab-paclitaxel and gemcitabine
Description: Dose and schedule per protocol

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTX-030 and pembrolizumab
Description: Dose and schedule per protocol

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTX-030, nab-paclitaxel and gemcitabine
Description: Dose and schedule per protocol

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Budigalimab and mFOLFOX6
Description: Dose and schedule per protocol
Study: NCT00878254

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Granulocyte-colony stimulating factor (G-CSF) 480 mcg subcutaneously (SQ) starting on Day 13 of Cycles 1 and 3; and Day 7 of Cycles 2 and 4, per study protocol.
Study: NCT01864109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna 2,100 mg/m2 (or 70 mg/kg if \< 10 yrs of age) administered intravenously in concordance with institutional pediatric administration guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna 2,100 mg/m2 (or 70 mg/kg if \< 10 yrs of age) administered intravenously in concordance with institutional pediatric administration guidelines.
Study: NCT01864109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: Dexrazoxane 375 mg/m2 intravenously over approximately 15-30 minutes and as clinically indicated. To be administered immediately prior to doxorubicin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: Dexrazoxane 375 mg/m2 intravenously over approximately 15-30 minutes and as clinically indicated. To be administered immediately prior to doxorubicin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF-to be administered after the completion of appropriate chemotherapy cycles as per institutional guidelines.